BIO Insider Filing: Allison Schwartz Vested RSUs and Sold 55 Shares at $297.88

Rhea-AI Filing Summary

Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4 covering September 1, 2025. The filing shows vesting-driven acquisitions: 147 shares of Class A common stock were added on vesting of restricted stock units at no cash cost and 31, 42, and 74 RSUs vested (representing rights to 31, 42 and 74 shares). Following the transactions, Ms. Schwartz beneficially owned 1,452 shares of Class A common stock directly. The report also discloses a sale of 55 shares at $297.88 each, reducing direct holdings to 1,397 shares. The filing reflects routine executive equity compensation and a small open-market sale.

Positive

• Vesting of RSUs converted to 147 shares at no cash outlay, reflecting compensation retention mechanisms
• Detailed explanations tie vested restricted stock units to grant years (2021, 2022, 2023), improving transparency

Negative

• Small open-market sale of 55 shares at $297.88 reduced direct holdings, though amount appears immaterial

Insights

Securities Analyst

TL;DR: Routine insider vesting and a small sale; no material change to control or ownership.

The Form 4 documents standard equity compensation activity: restricted stock units vested and converted into Class A shares, increasing direct beneficial ownership by 147 shares net of a 55-share sale at $297.88. The sizes involved (single- to low-hundreds of shares) are immaterial relative to a public company’s outstanding capital and do not indicate a change in corporate control or a large liquidity event. This is consistent with scheduled vesting and occasional portfolio rebalancing by insiders.

Corporate Governance Expert

TL;DR: Disclosure is timely and complete for reported transactions; shows compliance with Section 16 reporting.

The filing includes necessary detail: transaction codes, quantities, prices, and an explanatory note tying vested RSUs to grant years (2021–2023) with multi-year vesting schedules. The explicit explanation of the origin of RSUs improves transparency. No departures, option exercises, or atypical grants are reported, suggesting ordinary-course equity compensation activity for a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allison Schwartz

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/01/2025		M		147(1)	A	$0	1,452	D
Bio-Rad A Common Stock	09/01/2025		F		55	D	$297.88	1,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/01/2025		M			31	(3)	(3)	Bio-Rad A Common Stock	31	$0	0	D
Restricted Stock Units	$0(2)	09/01/2025		M			42	(4)	(4)	Bio-Rad A Common Stock	42	$0	42	D
Restricted Stock Units	$0(2)	09/01/2025		M			74	(5)	(5)	Bio-Rad A Common Stock	74	$0	150	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

4. On September 1, 2022, the reporting person was granted 167 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

5. On September 1, 2023, the reporting person was granted 298 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Allison Schwartz	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Allison Schwartz report on Form 4 for BIO?

The report shows vesting of restricted stock units resulting in 147 Class A shares acquired and a sale of 55 shares at $297.88 on 09/01/2025.

How many Bio-Rad Class A shares does Allison Schwartz beneficially own after these transactions?

Following the reported transactions, Ms. Schwartz beneficially owned 1,452 Class A shares before the sale and 1,397 shares after the sale, per the Form 4.

Were the acquired shares purchased or issued from vested RSUs?

The acquired shares resulted from the vesting of restricted stock units; the filing states each RSU represents a right to one share and were acquired at $0 on vesting.

Do the transactions indicate any change in control or significant insider movement?

No. The transactions are routine compensation vesting and a small sale; quantities are in the low hundreds and do not indicate a change in control.

What grant years produced the vested RSUs reported?

Explanations identify RSU grants from 09/01/2021 (122 RSUs), 09/01/2022 (167 RSUs), and 09/01/2023 (298 RSUs) with multi-year vesting schedules.